SLC9A9-AS1

Across TCGA pan-cancer cohorts, SLC9A9-AS1 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated SLC9A9-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLC9A9-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SLC9A9-AS1 expression acts as an unfavorable survival marker, although some lineages such as LUSC and ESCA show a favorable association.

LIHC, LUSC, and MESO are the cancer types where SLC9A9-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.175	0.627	<.001	63	view →
LUSC	OS	Tertile	II,III,IV	0.859	0.706	.006	48	view →
MESO	OS	Tertile	All	0.092	0.559	.003	45	view →
UCEC	DFS	Tertile	IV	0.257	0.721	.005	36	view →
ESCA	DFS	Quartile	III,IV	0.682	0.260	.003	16	view →
GBM	OS	Tertile	All	0.663	0.382	.016	12	view →
KIRP	DFS	Tertile	All	0.809	0.932	.009	9	view →
BRCA	OS	Tertile	III,IV	0.766	0.917	.045	6	view →
THYM	OS	Median	All	1.000	0.696	.022	4	view →
THCA	OS	Quartile	II,III,IV	0.323	0.957	.025	4	view →
KICH	DFS	Tertile	All	0.460	0.878	.014	3	view →
DLBC	OS	Quartile	III,IV	0.172	1.000	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

SLC9A9-AS1–LIHC (OS)

Open the LIHC breakdown →